| ObjectiveTo evaluate the efficacy and safety of chemotherapy for advanced biliary tract carcinoma.Methods37cases of pathologically confirmed advanced biliary tract carcinoma in our oncology department from January2010to March2013were included in our study.25patients had cancers of intrahepatic cholangiocarcinoma,7patients had gallbladder cancer, and5patients had extrahepatic cholangiocarcinoma. The following data were analyzed:disease control rate (DCR), progression free survival (PFS), rate of response (RR) to first and second line of chemotherapy, overall survival (OS) and drug toxicity.Results36patients were assessable for response, and response rate was16.7%and disease control rate was77.8%. The median PFS was5.9months (95%CI,4.7-7.0), and median OS for34patients was15.4months (95%CI,7.5-23.3).28patients accepted cisplatin plus gemcitabine as first-line chemotherapy, and response rate was17.9%and disease control rate was78.6%. The median PFS was5.8months (95%CI,4.8-6.9) in the cisplatin-gemcitabine group. The median OS was16.2months (95%CI,6.1-26.3) in the cisplatin-gemcitabine group and10months (95%CI,6.6-13.4) in the second group patients who received other regimens.16patients had second-line chemotherapy and DCR was43.8%. The median OS for patients who received second-line chemotherapy was similar with those who didn’t have second-line chemotherapy (15.4months vs15.3months, P=0.435).9patients had gemcitabine-based chemotherapy as first-line chemotherapy and S-1as second-line chemotherapy and7patients were assessable for response. The DCR was42.9%. Patients had the GP regimen were evaluated for toxicities. The grades3or4neutropenia, thrombocytopenia and hepatotoxicity were observed in7patients (30.4%),3patients (13.0%), and3patients (13.0%) respectively.ConclusionsGP regimen is effective and well tolerated in patients with advanced biliary tract carcinoma. The curative effect of S-1as second-line chemotherapy in patients with advanced biliary tract carcinoma can’t be confirmed. |
PDF Full Text Request